Brukinsa
Generic name:zanubrutinib [ ZAN-ue-BROO-ti-nib ]
Drug class:BTK inhibitors
What is Brukinsa?
Brukinsa (zanubrutinib) is a prescription medicine used to treat certain types of B-cell lymphoma.
Brukinsa belongs to the class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors which work by blocking the growth and spread of cancerous B cells.
What is Brukinsa used for?
Brukinsa is used to treat adults with:
- Mantle cell lymphoma* (MCL) who have received at least one prior treatment for their cancer.
- Waldenström’s macroglobulinemia (WM).
- Marginal zone lymphoma* (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.
*Brukinsa was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to this medicine, but further studies are needed.
It is not known if Brukinsa is safe and effective in children.
Warnings
Using Brukinsa may increase your risk of developing other cancers, such as skin cancer. Ask your doctor about this risk and what skin symptoms to watch for. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.
Tell your doctor if you have ever had liver disease.
You may need to have a negative pregnancy test before you start using Brukinsa.
Before taking this medicine
Before you start treatment with Brukinsa, tell your healthcare provider about all of your medical conditions, including if you:
- have bleeding problems.
- have had recent surgery or plan to have surgery. Your healthcare provider may stop Brukinsa for any planned medical, surgical, or dental procedure.
- have an infection.
- have or had heart rhythm problems.
- have high blood pressure.
- have liver problems, including a history of hepatitis B virus (HBV) infection.
- are pregnant or plan to become pregnant. Zanubrutinib can harm your unborn baby. If you are able to become pregnant, your healthcare provider may do a pregnancy test before starting treatment with this medicine.
- Females should not become pregnant during treatment and for at least 1 week after the last dose. You should use effective birth control (contraception) during treatment and for at least 1 week after the last dose.
- Males should avoid getting female partners pregnant during treatment and for at least 1 week after the last dose of Brukinsa. You should use effective birth control (contraception) during treatment and for at least 1 week after the last dose.
- are breastfeeding or plan to breastfeed. It is not known if zanubrutinib pas..
